SCHEMBL483264

SCHEMBL483264

CC1CC(OC(N)=O)c2cc3c(cc2N1Cc1ccccc1)OCO3

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.44
BRD4 O60885 1/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 3/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.38
SIRT1 Q96EB6 1/20 0.38
ITGB1 P05556 1/20 0.37
ITGA4 P13612 1/20 0.37
CYP19A1 P11511 1/20 0.37
CACNA1G O43497 2/20 0.37
CACNA1H O95180 2/20 0.37
CACNA1I Q9P0X4 2/20 0.37
HPGD P15428 2/20 0.37
ALDH1A1 P00352 1/20 0.37
GSK3B P49841 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL483269 0.83 NR3C2 (0.41) PTGDR2LMNAMAPT
SCHEMBL482474 0.74 SMN1; SMN2 (0.45) PTGDR2BRD4LMNASMN1; SMN2TSHR
SCHEMBL482786 0.72 PTGDR2 (0.42) PTGDR2BRD4LMNASMN1; SMN2TSHR
SCHEMBL482790 0.71 PTGDR2 (0.39) PTGDR2BRD4TSHRMEN1KMT2A
SCHEMBL482473 0.69 ABCB1 (0.40) BRD4SMN1; SMN2TSHRNPSR1SIRT2
SCHEMBL482339 0.66 BRD4 (0.40) PTGDR2BRD4LMNASMN1; SMN2TSHR
SCHEMBL483265 0.64 TSHR (0.35) TSHRSIRT2SIRT1
SCHEMBL28485844 0.63 LMNA (0.57) PTGDR2LMNASMN1; SMN2TSHRNPSR1
SCHEMBL18581951 0.62 MEN1 (0.46) PTGDR2BRD4LMNAMAPTMEN1
Oxalic Acid SCHEMBL10471438 0.62 SLC6A12 (0.50) LMNASMN1; SMN2TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604030-B2 Fused piperidine compound and pharmaceutical containing same KOWA COMPANY, LTD. (JP) 2013-12-10 US disclosed
US-20120108581-A1 FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME KOWA COMPANY, LTD (JP) 2012-05-03 US disclosed
EP-2412710-A1 FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2012-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108581-A1 FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME EPOR, JAK2, HBZ PTGDR2 120/4885BRD4 1271/4885LMNA 4222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.